Sugi Predict

Sugi Predict / Compounds / SCHEMBL1306884

SCHEMBL1306884

SCHEMBL1306884

CC(C)N1CCC(NC(=O)C(=CCCCCC(=O)NO)COc2cccc3ccccc23)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 7/20 0.40
▸ HDAC6 Q9UBN7 7/20 0.40
▸ EHMT1 Q9H9B1 3/20 0.40
▸ HDAC3 O15379 4/20 0.39
▸ HDAC2 Q92769 3/20 0.39
▸ HDAC4 P56524 2/20 0.39
▸ HDAC7 Q8WUI4 2/20 0.39
▸ HDAC10 Q969S8 2/20 0.39
▸ HDAC11 Q96DB2 2/20 0.39
▸ HDAC8 Q9BY41 2/20 0.39
▸ HDAC9 Q9UKV0 2/20 0.39
▸ HDAC5 Q9UQL6 2/20 0.39
▸ P2RX3 P56373 1/20 0.39
▸ PREP P48147 1/20 0.38
▸ CASP1 P29466 2/20 0.38
▸ CASP3 P42574 2/20 0.38
▸ CASP7 P55210 2/20 0.38
▸ CASP8 Q14790 2/20 0.38
▸ EHMT2 Q96KQ7 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306881 1.00 HDAC1 (0.40) HDAC1HDAC6EHMT1HDAC3HDAC2
SCHEMBL29488460 1.00 HDAC1 (0.40) HDAC1HDAC6EHMT1HDAC3HDAC2
SCHEMBL29488476 0.95 P2RX3 (0.39) HDAC1HDAC6EHMT1HDAC3HDAC2
SCHEMBL1306861 0.95 P2RX3 (0.39) HDAC1HDAC6EHMT1HDAC3HDAC2
SCHEMBL1306864 0.95 P2RX3 (0.39) HDAC1HDAC6EHMT1HDAC3HDAC2
SCHEMBL1306271 0.92 ALDH1A1 (0.43) P2RX3PREPCASP1CASP3CASP7
SCHEMBL1306268 0.92 ALDH1A1 (0.43) P2RX3PREPCASP1CASP3CASP7
SCHEMBL1306855 0.91 CNR2 (0.39) P2RX3PREPCASP1CASP3CASP7
SCHEMBL1306856 0.91 CNR2 (0.39) P2RX3PREPCASP1CASP3CASP7
SCHEMBL1306220 0.89 P2RX3 (0.42) HDAC1HDAC6HDAC3HDAC2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US claimed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO claimed
EP-4026544-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY Crystalgenomics, Inc. (KR) 2022-07-13 — — EP claimed
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR CRYSTALGENOMICS, INC. (KR) 2021-11-11 — — US claimed
EP-3875081-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR Crystalgenomics, Inc. (KR) 2021-09-08 — — EP claimed
WO-2021045392-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY 크리스탈지노믹스(주) 2021-03-11 — — WO claimed
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2020-09-10 — — US claimed
EP-3640239-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2020-04-22 — — EP claimed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP claimed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US claimed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US claimed
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same CRYSTALGENOMICS, INC. (KR) 2023-05-23 — — US disclosed
EP-4155292-A1 METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE Crystalgenomics, Inc. (KR) 2023-03-29 — — EP disclosed
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US disclosed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO disclosed
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2020-09-10 — — US disclosed
EP-3640239-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2020-04-22 — — EP disclosed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP disclosed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US disclosed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY PDCD1, HDAC1, HDAC5 HDAC1 2/4885HDAC6 6/4885EHMT1 87/4885
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR AGPAT5, NOTUM, HADH HDAC1 2152/4885HDAC6 1912/4885EHMT1 2840/4885
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same DOHH, CYP51A1, ASAH2 HDAC1 2369/4885HDAC6 480/4885EHMT1 1963/4885
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC6 10/4885EHMT1 63/4885
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME DOHH, CYP51A1, CYP46A1 HDAC1 2705/4885HDAC6 592/4885EHMT1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback